See more : EV Digital Invest AG (ENGL.F) Income Statement Analysis – Financial Results
Complete financial analysis of Guardant Health, Inc. (GH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guardant Health, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- China Tungsten And Hightech Materals Co.,Ltd (000657.SZ) Income Statement Analysis – Financial Results
- Taiwan Navigation Co., Ltd. (2617.TW) Income Statement Analysis – Financial Results
- Beijing Yuanlong Yato Culture Dissemination Co.,Ltd. (002878.SZ) Income Statement Analysis – Financial Results
- C&G Systems Inc. (6633.T) Income Statement Analysis – Financial Results
- Edenville Energy Plc (EDL.L) Income Statement Analysis – Financial Results
Guardant Health, Inc. (GH)
About Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 563.95M | 449.54M | 373.65M | 286.73M | 214.38M | 90.64M | 49.84M | 25.25M |
| Cost of Revenue | 227.05M | 156.33M | 122.91M | 92.54M | 70.72M | 43.21M | 31.62M | 22.12M |
| Gross Profit | 336.90M | 293.21M | 250.74M | 194.20M | 143.66M | 47.43M | 18.22M | 3.13M |
| Gross Profit Ratio | 59.74% | 65.23% | 67.11% | 67.73% | 67.01% | 52.33% | 36.56% | 12.38% |
| Research & Development | 367.19M | 373.81M | 263.22M | 149.86M | 86.29M | 50.71M | 25.56M | 10.86M |
| General & Administrative | 155.80M | 163.96M | 206.64M | 192.77M | 61.40M | 36.19M | 36.78M | 9.92M |
| Selling & Marketing | 295.23M | 299.83M | 191.88M | 106.51M | 78.34M | 53.47M | 32.50M | 26.19M |
| SG&A | 451.03M | 463.78M | 398.52M | 299.28M | 139.73M | 89.66M | 69.27M | 36.11M |
| Other Expenses | 83.40M | -112.56M | 25.18M | 3.64M | 88.00K | 4.70M | -1.06M | -1.00K |
| Operating Expenses | 901.62M | 837.59M | 661.74M | 449.15M | 226.03M | 140.37M | 94.84M | 46.97M |
| Cost & Expenses | 1.13B | 993.92M | 784.65M | 541.68M | 296.75M | 183.58M | 126.45M | 69.10M |
| Interest Income | 35.37M | 6.07M | 3.93M | 10.17M | 13.74M | 5.27M | 2.23M | 733.00K |
| Interest Expense | 2.58M | 2.58M | 2.58M | 4.77M | 1.18M | 1.25M | 2.70M | 3.02M |
| Depreciation & Amortization | 42.88M | 35.96M | 22.27M | 16.07M | 13.61M | 7.14M | 5.21M | 3.69M |
| EBITDA | -433.31M | -614.91M | -359.62M | -225.07M | -54.93M | -75.84M | -75.31M | -39.42M |
| EBITDA Ratio | -76.83% | -144.79% | -102.21% | -84.10% | -31.97% | -91.54% | -140.91% | -156.13% |
| Operating Income | -564.73M | -544.38M | -411.00M | -254.95M | -82.37M | -92.94M | -76.61M | -43.85M |
| Operating Income Ratio | -100.14% | -121.10% | -110.00% | -88.92% | -38.42% | -102.54% | -153.71% | -173.66% |
| Total Other Income/Expenses | 85.96M | -109.07M | 26.53M | 9.05M | 12.65M | 8.72M | -6.60M | -2.29M |
| Income Before Tax | -478.76M | -653.45M | -384.47M | -245.90M | -69.72M | -84.23M | -83.21M | -46.13M |
| Income Before Tax Ratio | -84.90% | -145.36% | -102.89% | -85.76% | -32.52% | -92.92% | -166.96% | -182.71% |
| Income Tax Expense | 685.00K | 1.14M | 300.00K | 379.00K | -1.87M | 38.00K | 7.00K | 6.00K |
| Net Income | -479.45M | -654.59M | -384.77M | -246.28M | -67.85M | -85.06M | -83.22M | -46.14M |
| Net Income Ratio | -85.02% | -145.61% | -102.98% | -85.89% | -31.65% | -93.85% | -166.97% | -182.74% |
| EPS | -4.28 | -6.41 | -3.80 | -2.53 | -0.75 | -2.80 | -1.18 | -0.65 |
| EPS Diluted | -4.28 | -6.41 | -3.80 | -2.53 | -0.75 | -2.80 | -1.18 | -0.65 |
| Weighted Avg Shares Out | 111.99M | 102.18M | 101.31M | 97.50M | 90.60M | 30.40M | 70.72M | 70.72M |
| Weighted Avg Shares Out (Dil) | 111.99M | 102.18M | 101.31M | 97.50M | 90.60M | 30.40M | 70.72M | 70.72M |
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
Guardant Health (GH) Recently Broke Out Above the 200-Day Moving Average
Guardant Health Rockets After FDA Panel Recommends Approval For Blood-Based Colon Cancer Test
FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
U.S. FDA advisers back approval for Guardant's blood-based cancer test
Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
Guardant Health to Participate in Upcoming Investor Conferences
Trinity Industries, Inc. Announces Offering of Additional 7.750% Senior Notes Due 2028
Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
Amalgamated Bank Sells 981 Shares of Guardant Health, Inc. (NASDAQ:GH)
Source: https://incomestatements.info
Category: Stock Reports